LOI Agreement is steppingstone to formal agreement, The Multinational Pharmaceutical company is ranked in the top five contrast agent suppliers in the world, signaling and solidifying Voyageur’s importance in the global contrast agent market Calgary, Alberta, Canada – TheNewswire - December 20, 2024 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company") a vertically integrated...Read more
Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions LOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary Renovaro Cube (the “Cube”), a leader in specific AI-driven healthcare solutions, has entered into a strategic...Read more
FREMONT, Calif. / Dec 19, 2024 / Business Wire / Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize Personalis’ ImmunoID NeXT Platform® and...Read more
Collaboration to Focus on Nutrition, Cellular Rejuvenation, Protein, Collagen and Overall Wellness IM8, a New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com CHARLOTTE, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics’ (NASDAQ:PRE) IM8, a premium supplements brand focused on science-driven health solutions, is excited to announce a collaboration through a know-how agreement with Mayo Clinic to...Read more
Partnership launched with fully-contracted #CheckYourFoodTube Precancer Testing Event for Tuscaloosa firefighters NEW YORK, Dec. 19, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has entered into a strategic partnership with VITALExam LLC...Read more
BOSTON / Dec 19, 2024 / Business Wire / Today, 908 Devices Inc. (Nasdaq: MASS) and Getinge announce their collaboration to integrate Getinge’s bioreactors with 908 Devices’ MAVEN for automated control of glucose and lactate levels in cell cultures. The combined solution will help scientists measure critical process parameters in bioreactors, offering continuous, real-time analysis without the need for manual sampling. In the field of...Read more
Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging Novartis to pay up to $20M comprising upfront payments and research funding; BioAge may receive up to $530M in future long-term research, development, and commercial milestones RICHMOND, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) --...Read more
PALO ALTO, Calif. / Dec 18, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the Guardant360® CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib, an investigational covalent tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 while sparing epidermal...Read more
NEW YORK / Dec 18, 2024 / Business Wire / DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced an expanded partnership with SHL Telemedicine (NASDAQ: SHLT) to integrate the SmartHeart® portable 12-lead ECG device across DocGo mobile health care units. This expanded collaboration, initially launched in the New York-New Jersey area, will now bring advanced...Read more
Gilead and Terray Will Leverage Terray’s tNova Drug Discovery Platform to Identify Small Molecule Therapeutics Against Targets of Interest Gilead Has Exclusive Option to Develop and Commercialize Products from the Collaboration FOSTER CITY, Calif. & LOS ANGELES / Dec 17, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a...Read more
Preliminary Discussions Underway to Establish a Joint Venture SINGAPORE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it has entered into preliminary discussions with Guangdong Cell Biotech Co. Ltd. (“Guangdong Cell Biotech”), a...Read more
The term sheet is non-binding, subject to the execution of a definitive agreement Vancouver, Canada, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has signed a non-binding term...Read more
Expanded collaboration to yield greater biopharma access to Personalis’ MRD solution FREMONT, Calif. / Dec 16, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of...Read more
NEWTOWN, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Forian Inc. (Nasdaq: FORA), a leading provider of data science driven information and analytics solutions to the life science, healthcare and financial services industries, today announced a partnership with Databricks, the data and AI company, to deliver access to its Chartis™ product, which maps physician and organization affiliations, through Databricks Marketplace. This collaboration...Read more
DALLAS, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, today announced that national leaders in burn care have dedicated more than an estimated 511 in-person days of physician engagement to...Read more
CareDx Continues Strategic Expansion into Hematology Oncology with Pharmacokinetic and Monitoring Assays for Cell Therapy Patients BRISBANE, Calif. / Dec 11, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers –...Read more
EDINBURGH, Scotland, Dec. 11, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced a partnership with CareDx, Inc. (NASDAQ: CDNA) The Transplant Company™ who will perform pharmacokinetic analysis using its AlloCell™ solution in the ACHIEVE...Read more
PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with ImmunoGenesis, Inc. (“ImmunoGenesis”), a Houston-based clinical-stage biotechnology company developing science-driven immunotherapies. The collaboration focuses on the development of novel...Read more
Collaboration leverages NeuroBiogen’s research and development of novel oral tablet KDS2010 and Scilex’s commercial and development expertise in central nervous system (CNS) and primary care diseases. Novel oral tablet KDS2010, a recently synthesized potent, selective, and reversible MAO-B inhibitor will be the collaboration’s lead product candidate, targeting the fast growing $150 billion weight loss and Alzheimer’s disease...Read more
TORONTO, Dec. 9, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a premier artificial intelligence (AI) company that is transforming clinical trials in the pharmaceutical industry, is proud to announce that it has entered into a pilot collaboration agreement with a Top 5 pharmaceutical company. The pilot is seeking to unlock novel insights and hypotheses regarding...Read more
Vivo Empowers Clinical Development Teams to Accelerate Decision-making and Analyses in Clinical Trials for Improved Outcomes HOUSTON and BOCA RATON, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- OmniScience and INmune Bio (NASDAQ: INMB) today announced a pioneering partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer’s disease (AD) clinical trial (the “AD02 trial”) using OmniScience’s flagship...Read more
$10 Million Commitment from Specialty Drug Manufacturer to Support Commercialization Efforts SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the initiation of a strategic partnership with a...Read more
Solid Biosciences to collaborate with Mayo Clinic’s genetic cardiology disease laboratory Solid to receive exclusive worldwide licenses to AAV-based Suppression-Replacement gene therapy platform and multiple next-generation cardiac gene therapy programs developed by Mayo Clinic’s Windland Smith Rice Sudden Death Genomics Lab CHARLESTOWN, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the...Read more
RA'ANANA, Israel, Dec. 4, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN), (Nasdaq: IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking life support technology company, entered into a strategic collaboration with Westchester Medical Center in Valhalla, New York. Westchester Medical Center, the flagship hospital in the Westchester Medical Center Health Network, will evaluate the...Read more
Tuspetinib selected for a prestigious national clinical research program for ability to target broad spectrum of AML and MDS populations Trials to test tuspetinib in targeted drug combinations for frontline therapy of molecularly defined sub-groups of newly diagnosed AML and MDS SAN DIEGO and TORONTO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage...Read more
MINNEAPOLIS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ("OneMedNet" or the "Company"), a Real-World Data (RWD) platform — has announced its collaboration with Bayer's AI Innovation Platform (AIIP). By joining AIIP, the partnership aims to empower the developer teams of healthcare organizations and startups in building scalable and compliant AI-powered medical imaging software products. "We are thrilled to...Read more
Provides Update on SKNJCT-003 Phase 2 Clinical Study for Treatment of Nodular Basal Cell Carcinoma (BCC) Currently Underway in United States Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - December 2, 2024) - Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce an agreement with Swanielle Inc. ("Swanielle") to explore expansion of Phase 2 clinical study for treatment...Read more
Clinical trial collaboration and supply agreement enables pivotal Phase 3 OPERA-02 clinical trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancer; trial initiation expected in mid-2025 $250.0 million equity private placement with participation by new and existing investors including Adage Capital Partners LP, Bain Capital Life Sciences, BVF Partners L.P., Driehaus Capital Management, Janus...Read more
Siemens Healthineers and DeepHealth have signed a letter of intent to create AI-powered SmartTechnology™ to improve patient experience and operational efficiency in ultrasound. The collaboration aims to facilitate remote operations, collaboration, and enhanced interpretation capabilities for increased diagnostic accuracy and consistency by combining Siemens Healthineers’ Acuson Sequoia with RadNet’s DeepHealth SmartSonography™. A...Read more
Prototype development and feasibility testing underway for optimized subcutaneous delivery SARASOTA, FL, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a collaboration agreement with Kymanox for...Read more
Sarepta obtains exclusive worldwide licenses to four clinical-stage and three preclinical-stage programs in muscle, central nervous system, and rare pulmonary disorders, including potential best-in-class siRNA-based treatments for DM1 and FSHD Additionally, Arrowhead and Sarepta have entered into a discovery partnership pursuant to which Sarepta will nominate, and Arrowhead will deliver, IND-ready constructs for six targets across...Read more
Upon closing, Arrowhead will receive $825 million immediately, including an upfront payment and an equity investment at a 35% premium, and will receive an additional $250 million paid over five years Arrowhead has potential to receive an additional $300 million in near-term clinical trial enrollment-related milestone payments and is eligible for future potential milestone payments up to $10 billion and royalties on sales Sarepta to...Read more
FREMONT, Calif., Nov. 21, 2024 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated biotechnology company, and nCartes, Inc., a transformational cloud software platform provider, announced a collaboration agreement aimed at automating and streamlining the data fulfillment process for clinical trials. The goal of the collaboration is to make this essential process easier, faster, and less expensive for ImmunityBio's...Read more
SHANGHAI & CAMBRIDGE, Mass. / Nov 21, 2024 / Business Wire / Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic collaboration for the novel antibacterial drug XACDURO® (sulbactam-durlobactam) in mainland China. Pfizer’s affiliated companies will be exclusively authorized to undertake and perform certain commercialization activities for XACDURO® in mainland China. Through this...Read more
Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead U.S. development and commercial activities and book sales; Kyowa Kirin has exclusive commercialization rights outside the...Read more
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies. Myriad’s gold-standard Genomic Instability Score (GIS) to determine Homologous Recombination Deficiency (HRD) will be reported for all samples analyzed with Illumina’s...Read more
WALTHAM, Mass. / Nov 20, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties’ long and productive work history, this advanced collaboration is dedicated to accelerating Genomics England’s renowned research programs, supporting...Read more
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for immunology and inflammation (I&I)-related diseases, today announced a strategic research collaboration. Under the agreement, Mirador will...Read more
Collaboration will Drive AI-Powered Advancements in Next-Generation Protein Sequencing™ and Accelerated Data Processing BRANFORD, Conn. / Nov 20, 2024 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a collaboration with NVIDIA to develop its new proteomics platform, Proteus™, and advance Quantum-Si’s core technologies of amino acid binders...Read more
Sets stage for advanced scientific discovery of new diagnostic biomarkers and treatments for disease BRANFORD, Conn. & BLOOMINGTON, Minn. / Nov 20, 2024 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™ and SkyWaterTechnology (NASDAQ: SKYT), the trusted technology realization partner, announced today they will jointly expand their relationship to support...Read more
Lilly to Develop Two Targets Identified and Validated Using Verge Genomics’ AI-Enabled, All-in-Human CONVERGE® Platform Demonstration of the Robust Predictive Power of CONVERGE® - 83% of Prioritized Targets were Validated in Disease-Relevant Models, a Rate Significantly Higher than Industry Standards SOUTH SAN FRANCISCO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company pioneering the...Read more
Approximately €70 Million in Upfront and Near-term Payments to Cytokinetics Up to €490 Million in Commercial Milestone Payments, with Tiered Royalties on Future Sales SOUTH SAN FRANCISCO, Calif. and BERLIN, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Bayer today announced they have entered into a collaboration and license agreement for the exclusive development and commercialization of...Read more
Ratio to receive upfront, and potential milestones and tiered royalty payments BOSTON, Nov. 18, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS)....Read more
MINNEAPOLIS, Nov. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella™ fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau...Read more
MELBOURNE, Australia and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a technology collaboration and licence agreement with Berlin-based Eckert & Ziegler SE (EZAG) for the use of EZAG’s cyclotron-based systems to produce the alpha-emitting isotope, actinium-225 (225Ac). This provides Telix with both an additional commercial source of...Read more
Montreal, Canada, and Venlo, the Netherlands, Nov. 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration with the McGill University Centre for Microbiome Research to support microbiome research activities and outcomes. The three-year partnership will further drive microbiome sciences – the study of a community of microorganisms that can be found living together in any environment,...Read more
BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: TMO), through its subsidiary Life Technologies Corporation (“Thermo Fisher”), a world leader in supplying life sciences solutions and...Read more
CHICAGO / Nov 12, 2024 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology, to integrate its comprehensive genomic testing directly into Flatiron’s cloud-based Electronic Medical Record...Read more
INDIANAPOLIS and FLORHAM PARK, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpectronRx, a leading radiopharmaceutical contract developer and manufacturer, and Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, have signed a commercial supply agreement for the manufacture of Cellectar’s first-in-class...Read more
BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone of a previously announced partnership with Merck, known as MSD outside of the United States and Canada, focused on improving biologic manufacturing. As part of this milestone completion, Ginkgo will receive a research milestone payment of $9...Read more
CAMBRIDGE, Mass. & MONTREAL / Nov 12, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced a Cooperative Research and Development Agreement (CRADA) has been executed to advance the development of camonsertib as an anticancer agent in collaboration with the Cancer Therapy Evaluation Program (CTEP) of the US National Cancer...Read more
Collaboration will leverage Flare Therapeutics' proteomic and mass spectrometry platform and expertise, powered by its proprietary library of electrophilic compounds, to discover novel small molecules aimed at transcription factor targets in oncology Flare Therapeutics to receive US$70 million upfront, and potential milestone payments exceeding US$1.8 billion, as well as royalties CAMBRIDGE, Mass., Nov. 12, 2024 /PRNewswire/...Read more
Schrödinger to receive $150 million upfront and eligible to receive up to approximately $2.3 billion in milestone payments plus royalties Expanded multi-year software agreement enables technology deployment at significant scale across Novartis’s global research organization Schrödinger to host third quarter 2024 financial results webcast today at 8:00 a.m. ET NEW YORK / Nov 12, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR)...Read more
PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the...Read more
DENVER / Nov 11, 2024 / Business Wire / TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients suffering from liver cancer through its advanced delivery technology as well as an investigational immunotherapy, nelitolimod, has announced a strategic partnership with Geo-Med, LLC (“Geo-Med”), a certified Service-Disabled Veteran-Owned Small Business (SDVOSB),...Read more
Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ: PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of...Read more
Collaboration will leverage GE HealthCare’s legacy and scale of imaging innovation and RadNet’s DeepHealth AI-powered clinical and workflow solutions to further the innovation, commercialization, and adoption of AI in imaging. Together, GE HealthCare and RadNet’s DeepHealth aim to create SmartTechnology™ solutions that harness the power of AI to help redefine radiology workflows and address key challenges across the imaging value chain...Read more
Partnership Focuses on Improving Prior Authorization Process, Helping Drive Better Patient Outcomes WASHINGTON / Nov 07, 2024 / Business Wire / Humana Inc. (NYSE: HUM) and Evolent Health, Inc. (NYSE: EVH) announced they have expanded their strategic medical oncology partnership to modernize and streamline prior authorization processes to include radiation and surgical oncology services. By connecting all primary approaches to treating...Read more
Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China Agreement Provides Additional Validation for Clearside’s Suprachoroidal Space (SCS®) Delivery Platform ALPHARETTA, Ga., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...Read more
Company is advancing DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / November 7, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has extended its previously announced Research...Read more
AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the expansion of its co-marketing and distribution collaboration with BioReference Health, LLC (“BioReference”), a wholly-owned subsidiary of OPKO Health Inc. (NASDAQ: OPK), a multinational biopharmaceutical...Read more
NASHVILLE, Tenn. / Nov 07, 2024 / Business Wire / Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the nationwide launch of a new digital patient access solution in collaboration with Asembia, a leading provider of specialty pharmacy and patient support hub services. This multi-year exclusive partnership is designed to expand access to Harrow’s ophthalmic branded products, including FLAREX®,...Read more
REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced a co-marketing and sales agreement with Thermo Fisher Scientific, the world leader in serving science, to jointly promote Seer’s Proteograph™ Product Suite alongside Thermo Scientific Orbitrap Astral™ mass spectrometers. This strategic collaboration...Read more
BASKING RIDGE, N.J. and HELSINKI, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and Valo Therapeutics Oy (“ValoTx”), a private company developing novel, adaptable immunotherapies for the treatment of cancer, are pleased to announce a preclinical research collaboration...Read more
AUSTIN, Texas and INDIANAPOLIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, and SpectronRx, a leading radiopharmaceutical contract developer and manufacturer, announced the signing of a Manufacturing Services Agreement (MSA) for the production of Rhenium (186Re) Obisbemeda, an innovative...Read more
The companies expand partnership to enhance genetic variant interpretation for cancers and rare diseases BOSTON and ROLLE, Switzerland , Nov. 6, 2024 /PRNewswire-PRWeb/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven outcomes...Read more
Collaboration to leverage Praia Health’s technology and Labcorp’s comprehensive testing capabilities to streamline and personalize patient experience CHICAGO & BURLINGTON, N.C. / Nov 04, 2024 / Business Wire / Praia Health, the consumer experience orchestration platform for health systems, is pleased to announce it has secured a strategic investment from the Labcorp Venture Fund and will collaborate with Labcorp, a global leader of...Read more
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced a strategic research collaboration with privately-held TCGFB, Inc. (“TCGFB”) to discover antibody therapeutics targeting Transforming Growth Factor Beta (TGF-β) for the potential...Read more
The new platform services subscription contract with a top six U.S. pharma client marks a pivotal shift in Dario's pharma channel, transitioning the business model from milestone-based to recurring service subscription fees by expanding engagement with payors and pharmacy benefit managers (PBMs) NEW YORK, Nov. 4, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital...Read more
Collaboration leverages Ascendis’ proprietary TransCon™ technologies and Novo Nordisk’s expertise in cardiometabolic diseases Once-monthly GLP-1 receptor agonist will be the collaboration’s lead product candidate COPENHAGEN, Denmark, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to...Read more
VANCOUVER, Wash. and SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI) a data-first generative AI drug creation company, and Twist Bioscience Corporation (NASDAQ: TWST) a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today unveiled a collaboration to design a novel therapeutic using generative AI. “Bringing together two...Read more
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic challenges of cancer cell...Read more
Expanded agreement includes development of additional transgenic mouse technologies and performance of additional therapeutic antibody research programs FOSTER CITY, CA / ACCESSWIRE / October 31, 2024 / AbTherx, a biotechnology company with innovative technologies that enable and accelerate therapeutic antibody discovery and development, today announced the expansion of a previous agreement with Gilead Sciences, Inc. (Nasdaq:GILD) to...Read more
Toronto, Ontario--(Newsfile Corp. - October 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it has amended its agreement with Mayo Clinic, Rochester, Minnesota, US. The amendment is an extension of the Telo...Read more
FORT MYERS, FL, Oct. 29, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (OTCQX: AONC), one of the fastest-growing oncology networks in the United States, has partnered with Vantage Health Technologies to enhance access to and delivery of exceptional cancer care. Vantage’s AI-enabled platform provides real-time health data for actionable insights and next-best-actions that can promote better patient experiences and outcomes,...Read more
The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen. Collaboration leverages Neomorph's leading molecular glue discovery platform and Biogen’s deep expertise in Alzheimer’s, rare, and immunological diseases. CAMBRIDGE, Mass. and SAN DIEGO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to...Read more
WELL Health and HEALWELL AI announce the expansion of their multi-year agreement that allows WELL and HEALWELL to launch and manage clinical trial sites at WELL Health clinic locations across Canada. Leveraging HEALWELL's Contract Research Organization (CRO) capabilities alongside WELL Health's network of clinics across Canada, positions the partnership as a formidable player in AI-driven clinical trials, and opens up new revenue...Read more
Holliston, MA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, is proud to announce a new partnership with the renowned Capital Institute of Pediatrics in China to develop innovative treatments for...Read more
InStatin to secure exclusive worldwide licensing agreement of InVixa's inhaled statin solution to prevent and treat acute lung disease Toronto, Ontario--(Newsfile Corp. - October 28, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF), a leading developer and investment partner in advanced diagnostic and medical device technologies, is pleased to announce a significant development with its investment partners, InStatin and InVixa....Read more
The Israel Innovation Authority will fund Pluri and BIRAD's collaboration to advance MAIT Cell Therapy, led by Professor Cyrille Cohen, Head of the laboratory of tumor immunology and immunotherapy at Bar-Ilan University MAIT cells hold immense potential for immunotherapy and the treatment of solid tumors compared to conventional T-cells, but their expansion has been a challenge until Pluri announced its proprietary MAIT immunotherapy...Read more
FREEHOLD, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it entered into a memorandum of understanding (the “MOU”) with Qi Diagnostics Limited (“Qi Diagnostics”), a nanosensor-based diagnostic technologies company, to explore a proposed strategic collaboration to co-develop a VOC...Read more
Companies will discover and develop novel targets for the potential treatment of neuropsychiatric conditions New discovery program builds upon nearly two decades of partnership between AbbVie and Gedeon Richter NORTH CHICAGO, Ill. and BUDAPEST, Hungary, Oct. 24, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets...Read more
DEERFIELD, Ill. and PLEASANTON, Calif., Oct. 24, 2024 /PRNewswire/ -- Walgreens (Nasdaq: WBA), an integrated healthcare, pharmacy, and retail leader, and Veeva Systems (NYSE: VEEV) a leading provider of software, data, and services for the life sciences industry, today announced a long-term partnership to help life sciences companies improve patient outcomes.\ The partnership enriches Veeva Data Cloud products and...Read more
BOSTON and LONDON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) and Axovia Therapeutics Ltd. today announced a joint research collaboration designed to advance the understanding of Bardet-Biedl syndrome (BBS). “We believe there is a significant need and opportunity with the growing awareness of BBS to better understand the disease and its epidemiology,” said Prof. Phil Beales, Axovia Therapeutics’...Read more
Partnership Includes Early Access Program Enabling HLA Labs to be at the Forefront of Innovative Solutions for Donor-Recipient Matching New Data at Annual American Society for Histocompatibility and Immunogenetics Meeting Shows AlloSeq and LinkPrep Technology Enables High-Resolution Genotyping and Haplotyping without Family Studies BRISBANE, Calif. & SCOTTS VALLEY, Calif. / Oct 23, 2024 / Business Wire / CareDx, Inc. (Nasdaq:...Read more
Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value HAMBURG, GERMANY / ACCESSWIRE / October 23, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (MDAX/TecDAX, ISIN: DE0005664809) (NASDAQ:EVO) today announced progress within the...Read more
EDINBURGH, Scotland, Oct. 22, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into a research planning collaboration with Dr. Carlos Maluquer de Motes for the development of a treatment for Monkeypox. Dr. Carlos Maluquer de...Read more
The collaboration outlines plans for multiple in vivo studies, designed to test opaganib as a potential medical countermeasure to treat phosgene inhalation injury. The collaboration aims to determine whether opaganib can advance into further definitive U.S. government-sponsored development under the FDA's Animal Rule pathway to approval Used as a chemical weapon during World War I, phosgene, a toxic, colorless chemical, is today widely...Read more
Under the revised agreement, both companies will co-develop four Radio-DARPin programs; each company will have the right to commercialize two programs (previously one each) Molecular Partners will hold commercial rights to the second nominated Radio-DARPin Candidate, in addition to rights to first program MP0712 targeting DLL3 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ad hoc...Read more
CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio, today announced that they have entered into a collaboration and nonexclusive license agreement to combine...Read more
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE